Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Alzheimer's imaging showdown: which tracer is better?

NCT ID NCT05361382

Knowledge-focused Sponsor: Tharick Pascoal Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 09, 2026 · Updated 3 times

Summary

This study compares two different radioactive tracers used in PET scans to measure tau tangles in the brain, a hallmark of Alzheimer's disease. Researchers will scan over 800 participants with either Flortaucipir or MK-6240 to see how well they work over time. The goal is to harmonize these measurements so that future studies and clinics can use either tracer reliably.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Flortaucipir and MK-6240 (tau PET tracers)
What this could lead to
If successful, this could help standardize Alzheimer's imaging, making it easier to compare results across different studies and improve diagnosis.
What could go wrong
This is an early-phase observational study, not a treatment trial. It may not lead to immediate clinical changes, and the tracers may not be equally effective across all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

822 people

The number who actually took part.

Started

Mar 2022

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Have a study partner who will be able to provide an independent evaluation of functioning. * Willing and capable of undergoing repeated MR/PET imaging. * Fluent in a language approved by the coordinating center. * At screening, must have no cognitive impairment, or meet criteria for single- or multiple-domain amnestic mild cognitive impairment or Alzheimer's disease dementia. Exclusion criteria: * Inability to provide informed consent by self or by proxy. * Pregnant or breastfeeding women. * Have any condition or are taking any medication that could increase the risk to the participant, limit the ability to tolerate or interfere with the results of the tests and procedures (in the opinion of the investigator).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease tauopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease

Contacts and locations

Locations

  • Brown University

    Providence, Rhode Island, 02912, United States

  • Houston Methodist Neurological Institute

    Houston, Texas, 77030, United States

  • Lawrence Berkeley National Laboratory

    Berkeley, California, 94720, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • McGill University

    Montreal, Quebec, H3A 0G4, Canada

  • Sant Pau Biomedical Research Institute

    Barcelona, Spain, 08025, Spain

  • University of California San Francisco

    San Francisco, California, 94143, United States

  • University of Pittsburgh

    Pittsburgh, Pennsylvania, 15260, United States

  • Washington University in St. Louis

    St Louis, Missouri, 63130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.